Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting
Prostate cancer (PCa) is today the second most common cancer in the world, with almost 400,000 deaths annually. Multiple factors are involved in the etiology of PCa, such as older age, genetic mutations, ethnicity, diet, or inflammation. Modern treatment of PCa involves radical surgical treatment or...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/3/2939 |
| _version_ | 1797624204642746368 |
|---|---|
| author | Tomislav Pejčić Zoran Todorović Siniša Đurašević Lazar Popović |
| author_facet | Tomislav Pejčić Zoran Todorović Siniša Đurašević Lazar Popović |
| author_sort | Tomislav Pejčić |
| collection | DOAJ |
| description | Prostate cancer (PCa) is today the second most common cancer in the world, with almost 400,000 deaths annually. Multiple factors are involved in the etiology of PCa, such as older age, genetic mutations, ethnicity, diet, or inflammation. Modern treatment of PCa involves radical surgical treatment or radiation therapy in the stages when the tumor is limited to the prostate. When metastases develop, the standard procedure is androgen deprivation therapy, which aims to reduce the level of circulating testosterone, which is achieved by surgical or medical castration. However, when the level of testosterone decreases to the castration level, the tumor cells adapt to the new conditions through different mechanisms, which enable their unhindered growth and survival, despite the therapy. New knowledge about the biology of the so-called of castration-resistant PCa and the way it adapts to therapy will enable the development of new drugs, whose goal is to prolong the survival of patients with this stage of the disease, which will be discussed in this review. |
| first_indexed | 2024-03-11T09:39:38Z |
| format | Article |
| id | doaj.art-2c9f4ebe40ae4c1a9323f4ecd2b599a8 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T09:39:38Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-2c9f4ebe40ae4c1a9323f4ecd2b599a82023-11-16T17:04:40ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-02-01243293910.3390/ijms24032939Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic TargetingTomislav Pejčić0Zoran Todorović1Siniša Đurašević2Lazar Popović3Faculty of Medicine, University of Belgrade, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, 11000 Belgrade, SerbiaFaculty of Biology, University of Belgrade, 11000 Belgrade, SerbiaFaculty of Medicine, University of Novi Sad, 21000 Novi Sad, SerbiaProstate cancer (PCa) is today the second most common cancer in the world, with almost 400,000 deaths annually. Multiple factors are involved in the etiology of PCa, such as older age, genetic mutations, ethnicity, diet, or inflammation. Modern treatment of PCa involves radical surgical treatment or radiation therapy in the stages when the tumor is limited to the prostate. When metastases develop, the standard procedure is androgen deprivation therapy, which aims to reduce the level of circulating testosterone, which is achieved by surgical or medical castration. However, when the level of testosterone decreases to the castration level, the tumor cells adapt to the new conditions through different mechanisms, which enable their unhindered growth and survival, despite the therapy. New knowledge about the biology of the so-called of castration-resistant PCa and the way it adapts to therapy will enable the development of new drugs, whose goal is to prolong the survival of patients with this stage of the disease, which will be discussed in this review.https://www.mdpi.com/1422-0067/24/3/2939prostatecancertherapyantiandrogen resistancenew drugs |
| spellingShingle | Tomislav Pejčić Zoran Todorović Siniša Đurašević Lazar Popović Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting International Journal of Molecular Sciences prostate cancer therapy antiandrogen resistance new drugs |
| title | Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting |
| title_full | Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting |
| title_fullStr | Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting |
| title_full_unstemmed | Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting |
| title_short | Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting |
| title_sort | mechanisms of prostate cancer cells survival and their therapeutic targeting |
| topic | prostate cancer therapy antiandrogen resistance new drugs |
| url | https://www.mdpi.com/1422-0067/24/3/2939 |
| work_keys_str_mv | AT tomislavpejcic mechanismsofprostatecancercellssurvivalandtheirtherapeutictargeting AT zorantodorovic mechanismsofprostatecancercellssurvivalandtheirtherapeutictargeting AT sinisađurasevic mechanismsofprostatecancercellssurvivalandtheirtherapeutictargeting AT lazarpopovic mechanismsofprostatecancercellssurvivalandtheirtherapeutictargeting |